Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.64 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.63 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.63 |
| ▸ | CTSS | P25774 | 6/20 | 0.57 |
| ▸ | CTSK | P43235 | 5/20 | 0.57 |
| ▸ | CTSL | P07711 | 1/20 | 0.56 |
| ▸ | CTSB | P07858 | 1/20 | 0.56 |
| ▸ | PPARA | Q07869 | 6/20 | 0.55 |
| ▸ | PPARG | P37231 | 5/20 | 0.55 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.54 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.53 |
| ▸ | PPARD | Q03181 | 2/20 | 0.53 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.53 |
| ▸ | ITGAV | P06756 | 1/20 | 0.53 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9502547 | 1.00 | ACE (0.64) | ACEITGB3ITGA2BCTSSCTSK | |
| SCHEMBL7390262 | 0.89 | ACE (0.61) | ACEITGB3ITGA2BCTSSCTSK | |
| SCHEMBL5374891 | 0.89 | ACE (0.61) | ACEITGB3ITGA2BCTSSCTSK | |
| SCHEMBL1368753 | 0.89 | ACE (0.64) | ACEITGB3ITGA2BCTSSCTSK | |
| SCHEMBL1458942 | 0.89 | PPARA (0.65) | ACEITGB3ITGA2BCTSSCTSK | |
| SCHEMBL25284980 | 0.89 | ACE (0.64) | ACEITGB3ITGA2BCTSSCTSK | |
| SCHEMBL231980 | 0.89 | CTSS (0.71) | ACEITGB3ITGA2BCTSSCTSK | |
| SCHEMBL1310547 | 0.89 | CTSS (0.71) | ACEITGB3ITGA2BCTSSCTSK | |
| SCHEMBL25672 | 0.89 | PPARA (0.65) | ACEITGB3ITGA2BCTSSCTSK | |
| SCHEMBL5061931 | 0.89 | PPARA (0.65) | ACEITGB3ITGA2BCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105473575-B | Benzimidazolyl-methylurea derivatives as ALX receptor agonists | 爱杜西亚药品有限公司 | 2017-11-24 | — | — | CN | disclosed |
| EP-3030560-B1 | BENZIMIDAZOLYL-METHYL UREA DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2017-06-21 | — | — | EP | disclosed |
| US-9663473-B2 | Benzimidazolyl-methyl urea derivatives as ALX receptor agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2017-05-30 | — | — | US | disclosed |
| US-20160200686-A1 | BENZIMIDAZOLYL-METHYL UREA DERIVATIVES AS ALX RECEPTOR AGONISTS | IDORSIA PHARMACEUTICALS LTD (CH) | 2016-07-14 | — | — | US | disclosed |
| EP-3030560-A1 | BENZIMIDAZOLYL-METHYL UREA DERIVATIVES AS ALX RECEPTOR AGONISTS | Actelion Pharmaceuticals Ltd (CH) | 2016-06-15 | — | — | EP | disclosed |
| WO-2015019325-A1 | BENZIMIDAZOLYL-METHYL UREA DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200686-A1 | BENZIMIDAZOLYL-METHYL UREA DERIVATIVES AS ALX RECEPTOR AGONISTS | UTS2R, ADORA3, P2RX7 | ACE 1748/4885ITGB3 3095/4885ITGA2B 2699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.